adham jurdi, md | different options when it comes to mrd testing from a ctdna standpoint
Published 4 years ago • 70 plays • Length 1:16Download video MP4
Download video MP3
Similar videos
-
9:00
adham jurdi, md | ctdna and mrd testing with the expanded access program
-
2:59
adham jurdi, md | importance of ctdna and mrd testing
-
2:57
adham jurdi, md | patient case using ctdna and mrd testing
-
1:55
adham jurdi, md | expanded access programs during covid19
-
5:34
farshid dayyani, md | ctdna and mrd testing with the expanded access program
-
12:01
debate: is circulating tumor dna ready to guide adjuvant therapy in colon cancer? - yes
-
1:02
ctdna testing for mrd – reliable, sensitive, and specific, but challenges remain: 2022 esmo florida
-
58:52
ctdna and mrd | 2023 best of gi cancer conference
-
3:13
alamin: sintomas, sanhi, at paglaban sa kanser sa baga
-
3:25
understand ctdna testing
-
1:08
adham jurdi, md | importance of surveillance during covid-19
-
46:53
ctdna and mrd: who, when, and then what? | 2022 evolution conference
-
2:47
pathology innovation leaders forum: pd-l1 testing landscape - dr julien adam
-
2:33
linking the diagnosis-to-treatment interval with ctdna
-
4:41
neuroendocrine tumors - well differentiated is not the grade
-
39:38
precision medicine & clinical trials with anand karnad, m.d.
-
9:29
what is mrd and when should it be tested?
-
4:49
unmet needs in the adjuvant setting for renal cell carcinoma
-
1:34
precision oncology: rajen mody, md on genetic sequencing for childhood cancer
-
2:25
jairus ibabao, md | medical oncology and hematology
-
2:53
andrew feinberg, m.d. | johns hopkins medicine